To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.
FORMAT: Monograph
RELEASE DATE: February 1, 2020
EXPIRATION DATE: February 1, 2021
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™; 1.5 contact hours; 1.5 ACHE Qualified Education Hours
Please click on the appropriate link to view the CME/CE monograph and receive your credit:
If you are a PHYSICIAN: Click Here
If you are a PHARMACIST: Click Here
If you are a MANAGED CARE EXECUTIVE: Click Here
For all other users, Click Here
Target Audience
This activity is intended for managed care clinical and nonclinical executives engaged in the care of patients with diabetic retinopathy (DR) and diabetic macular edema (DME).
Educational Objectives
After completing this activity, the participant should be better able to:
- Compare anatomic and visual outcomes associated with various treatments for DR and DME
- Evaluate evidence supporting individualized treatment strategies for patients with DR and DME
- Apply evidence-based approaches to optimize value-based treatment selection for DR and DME
- Provide accurate and appropriate counsel as part of the treatment team
Joint Accreditation Statement

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-1070-H01-P)
Type of Activity: Application
ACHE Qualified Education
By attending Evidence for Change: Maximizing Outcomes in Diabetic Retinopathy and Diabetic Macular Edema offered by Postgraduate Institute for Medicine, participants may earn up to 1.5 ACHE Qualified Education Hours toward initial certification or recertification of the Fellow of the American College of Healthcare Executives (FACHE) designation.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Gary Owens, MD
Fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speakers’ bureaus) from Regeneron Pharmaceuticals, Inc
Dante J. Pieramici, MD
Consulting fees from Adverum; Allegro Ophthalmics, LLC; Gemini Therapeutics; Genentech, Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; and Regenxbio Inc
Contracted research from Adverum; Aerie Pharmaceuticals, Inc; Apellis Pharmaceuticals; Chengdu Kanghong Pharmaceutical Group Co Ltd; Gemini Therapeutics; Genentech, Inc; Ionis Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Santen Inc; and Stealth BioTherapeutics Inc
Ankoor R. Shah, MD
Consulting fees from Novartis Pharmaceuticals Corporation and Ocular Therapeutix, Inc
Winston Wong, PharmD
Consulting fees from AstraZeneca; Pfizer Inc; and Relypsa Inc
Planners, Managers, and Reviewers
The PIM planners, managers, and reviewers have nothing to disclose. The MedEdicus planners, managers, and reviewers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving ACHE/CME/CE credit for this activity. During the period February 1, 2020, through February 1, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Monograph
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
This ACHE/CME/CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 183 CLICK ONE OF THE OPTIONS ABOVE TO PROCEED